Cancer

For a company of our size, we are aiming in oncology to become:

A three-pronged approach to our oncology strategy

1. Target hard-to-treat cancers
   Guided by patient needs, we strive to develop major therapeutic innovations in areas where needs are greatest. We wish to initiate therapeutic progress where generally speaking needs are not yet met, known as hard-to-treat cancers, such as digestive cancers (stomach cancer, pancreatic cancer, and cholangiocarcinoma, a rare and aggressive form of bile duct cancer), glioma, or brain tumors, hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma) and pediatric cancers.
2. Concentrate on promising and complementary therapeutic approaches
   Servier concentrates its R&D programs in oncology in two promising areas:
   • Immuno-oncology, to activate the immune system against cancer cells ;
   • Targeted therapies, to specifically target one of the biological mechanisms of cancer cells.
3. Draw on a wide range of expertise
   Our teams boast a high level of expertise, which is why we encourage cross-divisional collaboration through our various research centers throughout the world. All our R&D centers work in a collaborative manner, pooling their remarkable expertise through cutting-edge technology platforms:
   • Our R&D center in Boston is located in the heart of one of the world’s most innovative health ecosystems ;
   • Symphogen in Denmark is our high quality monoclonal and bi-specific antibody center of excellence ;
   • Our future Servier R&D Institute at Paris-Saclay, which will open its doors in 2023

To step up the pace of research and development in innovative treatments, we unrelentingly promote and pursue open innovation with pharmaceutical labs, biotech companies, prestigious academic institutions and start-ups.

In oncology, we have formed around 40 research partnerships and collaborations.

For patients

Digestive cancers

Understanding digestive cancers: Insight

• Stomach cancer, a gastric disease
• Bowel cancer, where screening still occurs too late
• Cancer of the pancreas, where diagnosis comes too late

Improving patients’ quality of life

We have published a number of brochures and videos developed in collaboration with expert patients, patient representatives, carers and health care professionals. Designed for patients living with digestive cancers to support them, as well as their family, throughout their cancer journey, these materials form part of SHAPE,² an international program launched by Servier in collaboration with Digestive Cancers Europe.

00:00 / 00:00